It does not distinguish fat mass, lean mass, or changes in physical strength. That's why Co-Pilot looks beyond a single reading.
Body-composition estimates and functional measures can add context; neither is a diagnosis.
THE SCIENCE BEHIND THE QUESTION
Three facts. One reason to look closer.
GLP-1 treatment can deliver important health benefits. These trial findings show why tracking and maintenance conversations matter.
SURMOUNT-1 / 2025
25%
Of weight lost was lean mass.
In a DXA substudy, about three-quarters of weight lost on tirzepatide was fat mass and one-quarter was lean mass.
160 participants, 72 weeks. Lean mass is not identical to skeletal muscle. Read research ↗
PLATEAU / 2025
88–90%
Reached a defined plateau by week 72.
Weight loss tends to slow over time. A plateau does not automatically mean treatment has failed.
Post-hoc SURMOUNT-1 analysis; selected adherent participants who lost ≥5%. Read research ↗
MAINTENANCE / 2024
14%
Average regain after withdrawal.
In a randomised withdrawal trial, those switched from tirzepatide to placebo regained an average of 14% over 52 weeks.
SURMOUNT-4, selected trial participants. Never change treatment without your prescriber. Read research ↗
Research figures describe selected study groups, not your personal risk or expected outcome. Changes in lean mass do not establish an equivalent change in skeletal muscle or strength. View evidence and limitations.
INTERACTIVE / THE SCALE VS THE STORY
12 kg down. What actually changed?
One illustrative example makes the invisible visible. Switch perspectives to see why the total is not enough.
ILLUSTRATIVE EXAMPLE · NOT PERSONAL DATA
The same −12 kg. Two different views.
The scale tells you how much weight changed. A composition assessment can help estimate how much of the change is fat versus lean mass.
The 75/25 split is based on average proportions in one 160-person DXA substudy and is used here solely to illustrate a hypothetical 12 kg loss. It is not a prediction for any individual.
CHANGE IN WEIGHT
−12kg
−9.0 kgFat mass−3.0 kgLean mass
The scale tells you the total. It cannot separate fat from lean mass.
WHAT GLP-1 CO-PILOT IS HERE FOR
Not another prescription. A better-informed journey.
Track, learn, prepare and continue. The prescribing clinician stays in charge of medication and medical decisions.
01 / TRACK
See your trends.
Weight, available body-composition estimates and relevant functional observations.
02 / NOURISH
Ask about nutrition.
Protein, food quality and hydration are worth discussing, especially when appetite is reduced.
03 / PREPARE
Bring better questions.
Turn your observations into an informed conversation with your licensed care team.
04 / CONTINUE
Plan beyond the milestone.
Think about strength, maintenance, routines and long-term follow-up.
Co-Pilot describes an intended educational and progress-support pathway. Specific features and measurements depend on technical implementation, local authorisations, availability and consent.
BEFORE · DURING · BEYOND
Every phase has new questions.
Which stage describes your GLP-1 journey? Explore what deserves attention at each step.
01 / STARTING
Know your baseline.
Record your goals, initial weight and other relevant measurements; discuss nutrition, movement, medicines and expectations with your clinician.
Clear, useful starting points for your GLP-1 journey, not instructions to change treatment.
Am I losing fat or muscle?
A bathroom scale cannot tell. Body-composition measurements can estimate how fat mass and lean mass are changing, but each method has limitations. “Lean mass” also includes water and organs; it is not a direct measurement of muscle. Ask which assessment is appropriate for you and compare results taken under consistent conditions.
Am I eating enough protein?
Lower appetite may make adequate nutrition harder. A dietitian or other qualified clinician can help assess your needs, food intake, kidney health and other medical considerations. Do not treat an online protein target as a personal prescription.
Is my strength changing?
Track practical functional measures such as consistent, suitable strength exercises, mobility and how everyday tasks feel. Resistance exercise, where appropriate, can help preserve muscle during weight loss. Your care team should advise on a safe programme.
How am I responding over time?
Look beyond one weigh-in: consider the weight trend, estimated body composition, energy, nutrition, physical function, symptoms and clinician-reviewed tests. The meaning of each change depends on your history and how it was measured.
What should I discuss with my prescribing clinician?
Discuss troublesome side effects, hydration and nutrition, changes in strength or daily function, the pace of weight loss, medicine interactions, dose questions, plateaus and plans for ongoing care. Co-Pilot helps you prepare questions; it does not alter prescriptions.
How do I maintain my progress?
Maintenance is a distinct stage that merits a plan for nutrition, movement, follow-up and medication decisions with your prescriber. Weight regain can occur after treatment stops. Never stop, restart or change treatment because of content on this page.
Does a 25% lean-mass share mean I am losing 25% muscle?
No. The approximately 25% figure was an average share of weight lost as DXA-measured lean mass in a SURMOUNT-1 substudy, not a prediction for every person and not a pure muscle measurement. The accompanying fat-mass reduction was substantially larger.
If my weight loss plateaus, has my medication failed?
Not necessarily. Weight loss often slows and reaches a plateau, including in successful treatment. A plateau can be a transition to maintenance. Your prescriber can evaluate whether changes in symptoms, nutrition, treatment or follow-up need attention.
Walk into your next appointment better prepared.
Copy the six questions to discuss with your licensed prescriber, pharmacist or dietitian.
METAHUMAN BIOVOYAGER
See beyond the scale.
For Dubai, BioVoyager is the planned physical entry into a broader measurement and education journey. Join the Founders 500 waitlist to express interest.
The evidence does not prove that METAHUMAN services prevent muscle loss, prevent weight regain, predict individual response or improve clinical outcomes. No BioVoyager observation replaces DXA, a medical assessment or a clinician-led decision.
EDUCATIONAL COMPANIONSHIP
Know what changed. Know what to ask.
Co-Pilot is one of seven personal journeys. Its role is to help you understand applicable measurements, follow repeatable trends and prepare useful questions for your licensed prescribing clinician. It does not diagnose or change medication.
Founders 500 is an interest list, not a booking, treatment offer or guarantee of place. Submitting the Founders 500 form saves your registration and sends an acknowledgment email. Prescription medicines and clinical decisions remain under appropriately licensed medical professionals.